Talks
The first table lists my invited lectures and mini-courses, including a link to an online recording if available. Underneath, my presentations of papers at congresses are listed.
The first table lists my invited lectures and mini-courses, including a link to an online recording if available. Underneath, my presentations of papers at congresses are listed.
| Year | Presentation | Location | Link |
|---|---|---|---|
| 2024 | Lecture on "Starting right: aligning eligibility and treatment assignment at time zero when emulating a target trial" | Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, USA (online) | |
| 2024 | Lecture at JSN/ERA joint symposium | Japanese Society of Nephrology, Japan | |
| 2024 | Intermediate Course in Pharmacoepidemiology | Danish Society for Pharmacoepidemiology, Denmark | |
| 2024 | Lecture series (3 lectures) on target trial emulation | Dept of Clinical Epidemiology of Aarhus University, Denmark | Slides #2 Slides #3 |
| 2023 | Journal club clone-censor-weight | Harvard School of Public Health, USA | |
| 2023 | Lecture series (3 lectures) on target trial emulation | Karolinska Institute, Sweden | |
| 2023 | Lecture on "Drawing causal inference from observational studies in nephrology" | ERA congress Milan, Italy | Slides |
| 2023 | Stanley Shaldon Award Lecture | ERA congress Milan, Italy | YouTube |
| 2023 | Lecture on "Target trial emulation: what, why and how?" | Kidney Health Research Collaborative, UCSF, USA | |
| 2023 | Lecture on "Safety of SGLT-2 inhibitors vs. GLP-1RA in patients with CKD and type 2 diabetes: U.S. cohort study" | Renal Disease Interest Group, Johns Hopkins University, USA | |
| 2023 | Lecture on "Using clone-censor-weight to study deprescribing: an application to RAS inhibitors in advanced CKD patients" | NorPEN (Nordic Pharmacoepidemiological Network) | |
| 2023 | Lecture on "Clinical research: description, prediction, causality" | Dutch Surgical Society for Medical Students, LUMC, The Netherlands | |
| 2022 | Guest lecturer in Clinical Data Science course (CI732) | Harvard Medical School, USA | |
| 2022 | Lecture on "Target trial emulation - what, why and how?" | Nephrology Grand Rounds, Ottawa Hospital, Canada | YouTube |
| 2022 | Workshop on "Longitudinal data and time-to-event modelling" | LUMC, The Netherlands | |
| 2022 | Lecture on "Target trial emulation: A new standard for observational research" | University College London, UK | |
| 2022 | Lecture on "Implications for outcome studies on timing of dialysis initiation" (in the session "Why Nephrology needs Target Trial Emulation") | ERA-EDTA congress, Paris, France | |
| 2022 | Lecture on "Introduction to pharmaco-epidemiology" (Epidemiology Course: Advanced Statistical Approaches in Observational Clinical Research and Introduction to Pharmacoepidemiology) | World Congress of Nephrology | Slides |
| 2021 | Lecture on "Target trial emulation in nephrology using observational data - a new paradigm" | Department of Medical Informatics, Amsterdam UMC, The Netherlands | |
| 2021 | Lecture on "Effectiveness and safety of renin-angiotensin system inhibitors in advanced kidney disease: nationwide cohort studies" | Harvard Medical School, USA | |
| 2020 | Course coordinator for Medicine in Numbers | Pre-University, LUMC, The Netherlands | Course manual |
| 2020 | Lecture on "Association between renal function decline after RAS-blockade and cardiorenal outcomes" | Honour College, LUMC, The Netherlands | |
| 2019 | Lecture on "Association of acute increases in creatinine after renin-angiotensin system blockade with subsequent outcomes" | Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden | |
| 2018-2021 | Instructor Epidemiology, BSc/MSc Medicine and Biomedical Sciences | LUMC, The Netherlands |
| Congress | Presentation | Award |
|---|---|---|
| ERA 2024 | Effect of dialysis vs. conservative care on all-cause mortality in older patients with advanced CKD (senior author) | Best abstract by young author |
| ERA 2024 | Measured glomerular filtration rate and risk of adverse outcomes in 6,059 patients from the Stockholm CREAtinine Measurements (SCREAM) project | |
| ICPE 2023 | Effectiveness and safety of apixaban, rivaroxaban and warfarin in patients with advanced CKD and atrial fibrillation (free communication) | |
| ERA 2023 | Effectiveness and safety of apixaban, rivaroxaban and warfarin in patients with advanced CKD and atrial fibrillation | |
| ERA 2023 | Accuracy of estimated glomerular filtration rate equations in patients with discordances between creatinine and cystatin c-based estimations (moderated oral) | |
| ERA 2023 | Accuracy of novel GFR estimating equations based on creatinine, cystatin c or both in routine care (focused oral) | |
| ERA 2022 | Impact of removing race from the CKD-EPI equation: analysis of 1.6 million Swedish adults | Best abstract by young author |
| ERA-EDTA 2021 | When to initiate dialysis to reduce mortality and cardiovascular events in advanced CKD | Best abstract of congress |
| ERA-EDTA 2021 | Comparative effectiveness of SGLT2i versus DPP4i on cardiovascular and renal outcomes in routine-care settings (mini-oral) | |
| European Society of Cardiology 2020 | Association between beta-blocker use and mortality/morbidity in patients with heart failure and advanced CKD | Selected for advances in science session |
| Dutch Nephrology Days 2020 | Beta-blockers are associated with reduced mortality in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a cohort study | |
| ERA-EDTA 2020 | β-blockers are associated with reduced mortality in patients with heart failure with reduced ejection fraction and advanced CKD: cohort study | Best abstract presented by young author |
| ERA-EDTA 2020 | Comparative effectiveness of renin-angiotensin system inhibitors and calcium channel blockers in individuals with advanced chronic kidney disease: a nationwide cohort study | ERA-EDTA Social Media Award |
| ERA-EDTA 2019 | Long-term cardiorenal outcomes associated with the acute increase of plasma creatinine following renin-angiotensin system blockade in a real-world setting | Best abstract presented by young author |
| Dutch Nephrology Days 2019 | Renin-angiotensin system inhibition, mortality and cardiorenal outcomes in advanced chronic kidney disease |